Kamada Ltd.

Hello, and welcome to the Commodot Limited third quarter 2021 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Bob Yedit with LifeSci Advisors. Please go ahead, Bob.

Thank you, and thank you all for joining us. This is Bob Yetted from LifeSci Advisors. Joining me from Kamada are Amir London, Chief Executive Officer, and Jaime Orlev, Chief Financial Officer. Earlier this morning, Kamada announced a strategic transformational transaction, positioning the company as a global leader in plasmid-derived hyperimmune market through the acquisition of a portfolio of four FDA-approved plasmid-derived commercial products from Sayall Therapeutics, a privately held pharmaceutical company, as well as its financial results for the three and nine months ended September 30th, 2021. If you have not received these news releases, please go to the investor's page of the company's website. Before we begin, I'd like to caution the comments made during this conference called by management will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Comida. I encourage you to review the company's filings with securities and exchange commissions, including without limitation the company's forms 20F and 6K, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, Monday, November 22, 2021. Comida undertakes no obligation to revise or update any statements to reflect these events or circumstances after the date of this conference call. With those prepared remarks, it's my pleasure to turn the call over to Amir London, CEO. Amir?

Thank you, Bob. My thanks also to our investors and analysts for your interest in Kamada and for participating in today's call. I and all of us at Kamada are thrilled to announce this morning the strategic transformational transaction positioning Kamada as a global leader in the plasma-derived hyperimmune market through the acquisition of a portfolio of four FDA-approved plasma-derived hyperimmune commercial products from Cell Therapeutics. Before I continue to provide you with an overview of this strategic transaction, which is a significant growth catalyst for Kamada, I will ask Jaime to provide the key details around our financial results for the third quarter and the nine months ended September 30th. Jaime, please.

Thank you, Amir, and good day, everyone. Our business continues to perform as anticipated through the first nine months of 2021. In the third quarter of 2021, total revenues were $23 million compared to $35.3 million for the third quarter of 2020. For the first nine months of 2021, total revenues were $72.2 million down from the $101.7 million in the similar period of 2020. This decrease is primarily related to the expected reduction of Glacier sales resulting from the completion of the product manufacturing transition to Takeda. During the first nine months of 2021, we completed our committed supply of Glacier to Takeda and recognized revenues of approximately $26.9 million. As a reminder, we will begin receiving royalty payments in 2022 at a rate of 12% on Takeda's net in-market sales of Glacia through August 2025, and at a rate of 6% thereafter until 2040. We project receiving royalties in the range of $10 million to $20 million per year from 2022 to 2040. From a profitability standpoint, gross profit for the third quarter of 2021 was $5.7 million as compared to $14.8 million in the third quarter of 2020. For the first nine months of the year, our total gross profit was $23.7 million as compared to the $37.4 million of total gross profit in the first nine months of 2020. Gross margins for the third quarter and first nine months of the year were 22% and 32% respectively. as compared to 42% and 36%, respectively, in the equivalent periods in 2020. As a reminder, we said on our last call that we expected a shift in product sales mix during the second half of the year, resulting in lower gross margins. Net loss for the quarter was approximately $800,000, or two cents per share. as compared to net income of $6.8 million, or 15 cents per share, in the third quarter of 2020. For the first nine months of 2021, net income was $2.8 million, or 6 cents per share, as compared to net income of $15.5 million, or 35 cents per share, in the first nine months of 2020. For the first nine months of 2021, our adjusted EBITDA, excluding the one-time severance costs related to the workforce reduction was $6.7 million compared to $21.1 million in the first nine months of 2020. With that, let me return the call over to Amir for his overview of the strategic acquisition. Amir?

Thank you, Jaime. As mentioned earlier, we are thrilled with this strategic transformational transaction positioning Kamada as a global leader in the plasma-derived hyperimmune market through the acquisition of a portfolio of four FDA-approved plasma-derived commercial products. Collectively, these four products acquired from Cell Therapeutics are expected to generate global revenue for the full year of 2021 of between $40 to $45 million. Approximately 75% and 20% of these cells will be generated in the US and Canada, respectively. The acquired products expected full year 2021 gross margins are between 50 to 55%. Importantly, after the temporary decline in our revenues and profitability in 2021, compared to previous years, due to Glacier's manufacturing transfer to Takeda, the integration of the newly acquired portfolio with Kamada's existing business is expected to result in a significant growth in our revenues and profitability already next year in 2022. The four acquired products include. The first product is CytoGum, which currently accounts for approximately 50% of the portfolio revenue and is indicated for the prophylaxis of CMV disease associated with the transplantation of the kidney, lung, liver, pancreas, and heart. The product is the sole FDA-approved IgG product for this indication. You will recall that Kamada announced in late 2019 a contract manufacturing agreement. Such agreement was related to CytoGum. The tech transfer process for CytoGum is already well underway, and Kamada expects to receive FDA approval for manufacturing of the product and initiate commercial manufacturing at its facility in Israel by the end of 2022. The second product is Varizelig, indicated and recommended by the US Centers for Disease Control, the CDC, for post-exposure prophylaxis, or Varizela, in high-risk individuals, including immunocompromised children, newborns, and pregnant women. The product is the sole FDA-approved IgG product for this indication. The third product is WinRaw, indicated for use in ITP and suppression of resus isoimmunization during pregnancy and other obstructive conditions in non-synthesized RhoD-negative women. And the fourth product is HepagumB, indicated for use in the prevention of hepatitis B recurrence following liver transplants, as well as post-exposure prophylaxis. The acquisition of this FDA-approved commercial portfolio represents a critical strategic and synergetic transaction, and it's an important growth driver for Kamada. Our U.S. subsidiary, Kamada Inc., will be responsible for the commercialization of the product in the U.S., including direct sales to wholesalers and local distributors. Together with CADRAV and ChemRaw, our other commercial IgG products, our portfolio of commercial specialty plasma-derived hyperimmune therapies now include six products, and this is indicative of our global leadership position in the plasma-derived specialty hyperimmune market. With the establishment earlier this year of Kamada Plasma, our US-based plasma collection company, the acquisition of this new portfolio and the establishment of our US-based commercial operation, Kamada continues to advance its core objective of entering 2022 as a fully integrated specialty plasma company with strong commercial capabilities in the US market. Importantly, In addition to the establishment of a commercial presence in the U.S., this transaction adds eight new international markets to our current distribution network. These new markets are primarily in the Middle East, as shown on this map. Kamada now has a commercial footprint in over 30 countries. Each of these products offers significant growth potential for Kamada. and we intend to invest in the commercialization and lifecycle management of the newly acquired products, and to leverage our existing strong international distribution network to grow the acquired portfolio revenue in new geographic markets. Moreover, with the planned transfer of Cytega Manufacturing to our facility in Israel, the expected continued growth of CADRAP, our anti-REBI's hyperimmune product, and the potential to transfer the production of the other three products in the acquired portfolio to our Israeli facility, we anticipate utilizing and optimizing the capacity of our plant following the transition of Glacier Manufacturing to Takeda. In terms of the acquisition financial terms under the agreement, Commodites Bank sells $95 million upfront and up to an additional $50 million in sales milestones during 2022 until 2034. In addition, Kamada is acquiring from CERN existing inventory at an estimated value of approximately $15 million, which will be paid over 10 equal quarterly installments. All other inventory transferred at no cost. In addition to leveraging our current strong balance sheet, To partially fund the acquisition costs, Kamada has secured a $40 million credit facility for Banka Poalim, Israel's leading commercial bank. The credit facility is comprised of a $20 million five-year term loan and a $20 million short-term revolving credit facility. To summarize, this acquisition is an important step towards establishing Kamada as a global leader in the development, manufacturing, and commercialization of plasma-derived specialty IGGs. As a reminder, our strategies focus on driving profitable growth from our current commercial activities, as well as our plasma-derived product development and manufacturing expertise. Together with the existing growth catalysts comprising of credit upsells in the U.S. markets, relative royalties, our rapidly expanding Israeli distribution segment based on the anticipated launch of nine new biosimilar products, the cells of Glacia and existing hyper-immune cells in international markets, the establishment and expansion of our U.S.-based plasma collection capabilities, and the potential of our in-health AAT investigational product, today's announced acquisition of the four plasma-derived hyper-immune commercial products is transforming Kamada into a vertically integrated specialty plasma-derived company and a global leader in the plasma-derived hyperimmune market. In summary, we are highly confident in the strength of our overall business, which consists of multiple profitable lines of business that can each drive significant long-term growth opportunities for Kamada, and we look forward to leveraging the many benefits of the transformational transaction announced today. With that, we now open the call for questions. Operator?

Thank you. We'll now be conducting a question and answer session. If you'd like to be placed into question Q, please press star 1 on your telephone keypad. Once again, that's star 1 to be placed into question Q. You may press star 2 if you'd like to remove your question from the queue. For participants using speaker equipment, may be necessary to pick up your handset before pressing star one. One moment, please, while we poll for questions. Our first question today is coming from Anthony Patron from Jefferies. Your line is now live.

Thank you, and good morning. Congratulations on the transaction announced today. I'll have a few focused here and a few more broader, higher-level questions. So first, Amir, on the transaction announced today with Sol, Maybe just a little bit more on the revenue breakdown across the four products in the $40 to $45 million range, just how that breaks out across the four products, and maybe just the growth profile on the portfolio, and then I'll have a couple of follow-ups.

Okay, thank you, Anthony. So CytoGum is the largest product of the four, and it's currently selling approximately 50% of the portfolio. The second and third products are WinRaw and Epigam. They sell between $10 to $8 million approximately, or $8 to $12 depending on the year. And Varizig is selling less than the other three products. I believe it's around $3 to $6 million. This is the expectation for this year.

Okay, and then when you look at that combined, 40 to 45 million, is there a growth rate, an historical growth rate that you can share as well?

So we're looking into the future, and we believe that we can grow this portfolio significantly by mainly two aspects. One aspect, in the U.S. market, we plan on establishing a commercial team that will be promoting the product. The products are primarily focused on transplantation, so we are going to cover the main transplantation centers in the U.S. and we are going to be very active in promoting this treatment for the needed population. In addition, the fact that Canada already has currently a distribution network in over 20 countries, 25 to be precise, we believe that we can grow this business significantly outside of the U.S. Until today, the main focus was U.S. and Canada. As we've said, 95% of the current sales within those two territories and with Kamada existing infrastructure, we believe that we can drive significant growth outside the U.S. and Canada through our existing distribution channels.

That's helpful. And then maybe on the production side, Amir, is the current Kamada collection footprint enough to support the four products from a hyperimmune plasma standpoint on the collection side, or will Will the company have to go out there and acquire Hyper-IG plasma to support the portfolio?

So the products are being transferred to Kamada with an established supply chain, including plasma supply capabilities or contracts for the years to come. In addition to that, we are planning to grow our own existing Hyper-IMM collection based on Kamada plasma products. That was established beginning of the year, and we plan on being able to support majority of the plasma needed for those products through our own capabilities in the years to come. It will take time to build this capacity, but that's our plan. This is going to improve our cost of goods and will allow us to be even more competitive and to grow our profitability in the U.S. and ex-U.S. on those four products.

Here's a follow-up for Jaime just on the margin profile here. 50 to 55% gross margin. It does sound like there'll be investments to support the portfolio and other markets, both direct and indirect sales channels. And so maybe just how this flows through the P&L when you consider the operating expenses that are going to be layered on the operation. So a little bit on the margin profile down to, let's say, the EBT line.

So outside of the U.S., we are going to use our existing distribution channels, so we are not going to operate our own sales team, so we are not going to add to the operational cost in that regard. We are going to support the products, of course, from a marketing perspective and product management, and this is going to be part of the support we will need to give anyways to our U.S. affiliates, which is going to sell the product. In the U.S., the team is going to be focused and highly effective We believe that we need up to 15, one-five people that will be working on that portfolio in the U.S. market. And the reason that I'm saying that we can be highly focused is because it is for the transportation centers. We are going to focus on the few dozen main transportation centers in the U.S. market, and that's going to be our core business.

Great, and then maybe to just transition away from the transaction today on the base business, two quick follow-ups I'll get in the queue here. One just on the Takeda royalties as we look into the first year in 2022, the range 10 to 20 million is wide. Just wondering, is that to consider market fluctuations just in terms of Glassia being sold, or is it something specific in the agreement when you consider the range? And then maybe if you can just provide, as we look into 22 and 23, the next steps that we should be looking for on the INOVATE inhalable trial. Thanks and congratulations again.

Thank you. So on the Glacier Takeda royalties, it's not about fluctuation. As you may remember, we are starting with a 12% royalty, and then it goes down in August 2025 to 6%. So basically, Into 2022, when we start, it will be the higher range of the 10 to 20 million because it will be the 12%. And then starting in September 2025, it will drop by half. That's why we gave the range. So you can start with a higher number for the next few years until end of 2025. Great, great.

And then just on the Innovate trial. Yes, yes.

So the InHealth study, as you know, we are... In the phase three pivotal study under the USIND and the European CTA, we announced today as part of our quarterly earnings that we had a successful DSMB meeting, the Drug Safety Monitoring Board Review. So we are highly encouraged by the good feedback we received from that committee on the safety of the treatment. We are planning to continue, of course, and open additional sites of the study early 2022.

Thanks again.

Thank you. As a reminder, that's star one to be placed in the question queue. One moment please while we poll for further questions. We've reached the end of our question and answer session. I'd like to turn the floor back over to management for any further or closing comments.

Thank you, Operator. So in closing, we are thrilled with the today's transformational strategic acquisition of the four FDA-approved commercial products and remain confident in the prospects for our business, which consists of multiple profitable lines of business that can each drive significant long-term growth opportunities for Kamada. As already explained, importantly, after the temporary decline in our revenues and profitability this year compared to previous years as a result of Glacier manufacturing transfer to Takeda, The integration of the newly acquired portfolio with Commodore's existing business will result in significant growth in our revenues and profitability already next year in 2022. Thank you for joining us today, and we look forward to providing you with further updates in the coming weeks and months. We hope you all stay healthy and safe. Thank you very much.

Thank you. That does conclude today's teleconference. Let me just connect your line at this time and have a wonderful day. Thank you for your participation today.